Frederike K Engels

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Alternative drug formulations of docetaxel: a review
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Anticancer Drugs 18:95-103. 2007
  2. doi request reprint Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:353-62. 2011
  3. ncbi request reprint Docetaxel administration schedule: from fever to tears? A review of randomised studies
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 41:1117-26. 2005
  4. pmc Potential for improvement of docetaxel-based chemotherapy: a pharmacological review
    F K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Br J Cancer 93:173-7. 2005
  5. ncbi request reprint Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 17:63-7. 2006
  6. ncbi request reprint Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    Cancer Biol Ther 5:833-9. 2006
  7. ncbi request reprint Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Oncologist 12:291-300. 2007
  8. ncbi request reprint Influence of ketoconazole on the fecal and urinary disposition of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 60:569-79. 2007
  9. ncbi request reprint Medicinal cannabis in oncology
    Frederike K Engels
    Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Department of Medical Oncology, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Eur J Cancer 43:2638-44. 2007
  10. ncbi request reprint Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 75:448-54. 2004

Detail Information

Publications13

  1. ncbi request reprint Alternative drug formulations of docetaxel: a review
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Anticancer Drugs 18:95-103. 2007
    ....
  2. doi request reprint Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 17:353-62. 2011
    ..The purpose of this study was to evaluate the effect of PK-guided [area under the plasma concentration versus time curve (AUC) targeted], individualized docetaxel dosing on interindividual variability in exposure...
  3. ncbi request reprint Docetaxel administration schedule: from fever to tears? A review of randomised studies
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 41:1117-26. 2005
    ..Currently, 3-weekly docetaxel remains the standard schedule for treatment, whereas the weekly schedule offers a possibility of treatment individualisation for those patients where the risk of myelosuppression is considered unacceptable...
  4. pmc Potential for improvement of docetaxel-based chemotherapy: a pharmacological review
    F K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center Rotterdam, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Br J Cancer 93:173-7. 2005
    ....
  5. ncbi request reprint Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Drugs 17:63-7. 2006
    ..Combustion of tritiated feces and urine samples is a simple, rapid, sensitive, precise and reproducible method with high recovery. It can be applied to quantify [3H]docetaxel excretion after i.v. administration...
  6. ncbi request reprint Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus MC, Rotterdam, The Netherlands
    Cancer Biol Ther 5:833-9. 2006
    ..We investigated if high-dose ketoconazole, a potent CYP3A inhibitor, could result in a uniform reduction of docetaxel clearance and reduce the inter-individual variability in docetaxel AUC and clearance...
  7. ncbi request reprint Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Oncologist 12:291-300. 2007
    ....
  8. ncbi request reprint Influence of ketoconazole on the fecal and urinary disposition of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 60:569-79. 2007
    ....
  9. ncbi request reprint Medicinal cannabis in oncology
    Frederike K Engels
    Erasmus University Medical Centre Daniel den Hoed Cancer Centre, Department of Medical Oncology, Groene Hilledijk 301, 3075 EA, Rotterdam, The Netherlands
    Eur J Cancer 43:2638-44. 2007
    ....
  10. ncbi request reprint Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel
    Frederike K Engels
    Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Medical Center, Rotterdam, The Netherlands
    Clin Pharmacol Ther 75:448-54. 2004
    ..We investigated the effects of the potent CYP3A4 inhibitor ketoconazole on the pharmacokinetics of docetaxel in patients with cancer...
  11. pmc Application of prolonged microdialysis sampling in carboplatin-treated cancer patients
    Inge R H M Konings
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer Chemother Pharmacol 64:509-16. 2009
    ..We explored the feasibility of microdialysis in tumor tissue for multiple days in a clinical setting, using carboplatin as model drug...
  12. ncbi request reprint Medicinal cannabis in oncology practice: still a bridge too far?
    Floris A de Jong
    Department of Medical Oncology, Erasmus MC University Medical Center Rotterdam Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:2886-91. 2005
  13. pmc CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity
    Anne Joy M de Graan
    Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 19:3316-24. 2013
    ..Neurotoxicity is one of the most prominent side effects of paclitaxel. This study explores potential predictive pharmacokinetic and pharmacogenetic determinants for the onset and severity of neurotoxicity...